Category: clinical trial diversity

To make trials more inclusive, H1 wants to help find the right physicians

clinical trial diversity, Clinical Trials, Daily, H1, Health Services, Health Tech, New York, Startups, SYN, Top Story / September 2, 2021 September 2, 2021

The company rolled out a tool to help pharmaceutical companies pull together information about clinical trial sites and identify the best physician investigators for a trial.

CVS joins the decentralized clinical trials movement with launch of new biz unit

BioPharma, biopharma nl, clinical trial diversity, Clinical Trials, cvs, Daily, Pharma, Rhode Island, SYN, Top Story, Woonsocket / May 23, 2021 May 23, 2021

CVS has launched a new clinical trials services business that will help drug companies and contract research organizations recruit clinical trial volunteers. The new business unit builds on work the pharmacy giant did last year, identifying and recruiting recruit people for clinical trials testing Covid-vaccines and medicines.

Investors pour $91M into growing clinical-trial software firm

AliveCor, biopharma nl, California, clinical trial diversity, Clinical Trials, Daily, GSR Ventures, Health IT, Health Tech, Medable, News, Pharma, PPD, Sapphire Ventures, Software, Startups, Streamlined Ventures, SYN, Top Story / November 30, 2020 November 30, 2020

The Covid-19 pandemic is altering behavior and fueling demand for remote technologies in clinical trials with Medable, a company in the clinical trial software space, looking to capitalize.

BMS puts $300M toward diversity efforts, including clinical trial diversity

BioPharma, biopharma nl, BMS Foundation, Bristol-Myers Squibb, clinical trial diversity, Clinical Trials, coronavirus, COVID-19, Daily, New York, SARS-CoV-2, SYN, Top Story / August 14, 2020 August 14, 2020

The company plans to train 250 new racially and ethnically diverse clinical trial investigators and extend the reach of its trials to underserved rural and urban communities.

Trials of Gilead’s remdesivir in Covid-19 not diverse enough, experts write

BioPharma, biopharma nl, clinical trial diversity, coronavirus, COVID-19, Daily, Gilead Sciences, remdesivir, SARS-CoV-2, SYN, Top Story, Veklury / August 12, 2020 August 12, 2020

In a commentary, physicians and pharmacists wrote that percentages of Black, Latino and Native American patients in two Phase III studies of the drug that the company is using for FDA approval were disproportionate to Covid-19’s incidence in those communities.